Intellipharmaceutics International Inc
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, car… Read more
Intellipharmaceutics International Inc (IPCIF) - Total Liabilities
Latest total liabilities as of August 2023: $14.44 Million USD
Based on the latest financial reports, Intellipharmaceutics International Inc (IPCIF) has total liabilities worth $14.44 Million USD as of August 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Intellipharmaceutics International Inc - Total Liabilities Trend (2015–2022)
This chart illustrates how Intellipharmaceutics International Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Intellipharmaceutics International Inc Competitors by Total Liabilities
The table below lists competitors of Intellipharmaceutics International Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wahana Ottomitra Multiartha
JK:WOMF
|
Indonesia | Rp5.39 Trillion |
|
Real Heart
ST:HEART
|
Sweden | Skr13.59 Million |
|
Thunderbird Resources Ltd
AU:THB
|
Australia | AU$2.48 Million |
|
CJ Century Logistics Holdings Bhd
KLSE:7117
|
Malaysia | RM287.14 Million |
|
Plasson Indus
TA:PLSN
|
Israel | ILA989.96 Million |
|
Vertex Energy Inc
NASDAQ:VTNR
|
USA | $642.82 Million |
|
Euromedis Groupe SA
PA:ALEMG
|
France | €23.17 Million |
Liability Composition Analysis (2015–2022)
This chart breaks down Intellipharmaceutics International Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 9.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Intellipharmaceutics International Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Intellipharmaceutics International Inc (2015–2022)
The table below shows the annual total liabilities of Intellipharmaceutics International Inc from 2015 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-11-30 | $12.01 Million | +17.14% |
| 2021-11-30 | $10.25 Million | +5.68% |
| 2020-11-30 | $9.70 Million | +29.53% |
| 2019-11-30 | $7.49 Million | +1.59% |
| 2018-11-30 | $7.37 Million | +5.16% |
| 2017-11-30 | $7.01 Million | +2.22% |
| 2016-11-30 | $6.86 Million | +27.91% |
| 2015-11-30 | $5.36 Million | -- |